Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.34 | 0.84 | -4.09 | 0.00 |
| FCF Yield | 0.65% | -1.77% | -1.05% | -1.28% |
| EV / EBITDA | -166.53 | -95.87 | -72.97 | -103.72 |
| Quality | ||||
| ROIC | -3.48% | -5.47% | -6.34% | -8.22% |
| Gross Margin | 93.00% | 93.92% | 93.35% | 92.58% |
| Cash Conversion Ratio | -1.45 | 1.44 | 0.82 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | 194.24% | 187.01% | 103.38% | 92.08% |
| Free Cash Flow Growth | 153.79% | -43.06% | 22.06% | -205.06% |
| Safety | ||||
| Net Debt / EBITDA | 7.76 | 1.37 | 3.94 | 1.10 |
| Interest Coverage | 6.41 | -9.90 | -11.88 | -10.56 |
| Efficiency | ||||
| Inventory Turnover | 2.17 | 1.61 | 1.93 | 1.88 |
| Cash Conversion Cycle | 97.91 | -296.42 | -987.57 | -393.80 |